Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer

 Sanofi Signs a Non-Exclusive Clinical Collaboration Agreement with Mirati to Evaluate Adagrasib + SAR442720 (RMC-4630) in P-I/II Study for KRAS G12C-Mutated Lung Cancer

Shots:

  • The companies collaborated to evaluate Mirati’s adagrasib (KRASG12C inhibitor) + Sanofi’s SAR442720 (SHP2 inhibitor) in P-I/II dose-escalation & expansion study in patients with previously-treated NSCLC & KRASG12C mutations
  • Adagrasib & SAR442720 demonstrated an anti-tumor activity in pre-clinical models & both have complementary MoA
  • Sanofi will be responsible for sponsoring & operating the P-I/II study & both companies will share the cost of the study. Additionally, Adagrasib is being evaluated as monothx. and in combination with other anti-cancer therapies in patients with advanced KRASG12C-mutated solid tumors, including NSCLC, colorectal cancer & pancreatic cancer

Click here to read full press release/ article | Ref: PR Newswire | Image: Trading View

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post